Advanced Infliximab Model Now Available from DoseMe

JUPITER, Fla.--(BUSINESS WIRE)--DoseMe, a leading provider of model-informed precision dosing, today announced the availability of its Infliximab model. Infliximab (IFX) is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit tumor necrosis factor-alpha(TNFα). Anti-TNF agents, including infliximab, are the first biological agents effective in inducing and maintaining remission in inflammatory bowel disease (IBD)